Kee Kiat Yeo

Dear Editor, ALK-positive histiocytosis is a rare histiocytic neoplasm first described in 2008 and recently classified as a distinct entity [1, 2]. The disease is typically driven by KIF5B::ALK fusions and often involves the neurologic system [3, 4]. We previously conducted the largest study of ALK-positive histiocytosis to date, investigating 31 children and 8 adults with the disease [4].

Correction to: Nature Communications https://doi.org/10.1038/s41467-025-61820-z, published online 31 July 2025 In the version of the article initially published, there were errors in the ninth paragraph of the Results, where in the text now reading “Within the DFCI and KiTZ cohorts, in which all tumors underwent review by a pediatric neuropathologist, 85% (17/20) of all FGFR1 rearrangements and/or ITDs occurred in the context of pLGGs, versus 15% (3/20) in the pHGGs,” 85% (17/20) was...

Abstract Oncogenic alterations in fibroblast growth factor receptor (FGFR)-family proteins occur across cancers, including pediatric gliomas. Our genomic analysis of 11,635 gliomas across ages finds that 5.3% of all gliomas harbor FGFR alterations, with an incidence of almost 9% in pediatric gliomas. Alterations in FGFR proteins are differentially enriched by age, tumor grade, and histology, with FGFR1 alterations associated with glioneuronal histologies.